{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:10:19Z","timestamp":1769973019620,"version":"3.49.0"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Interventions"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1161\/circinterventions.113.001150","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T22:21:51Z","timestamp":1392762111000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":64,"title":["Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions"],"prefix":"10.1161","volume":"7","author":[{"given":"Davide","family":"Capodanno","sequence":"first","affiliation":[{"name":"From the Cardio-thoraco-vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.); and Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, FL (D.C., D.J.A)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"From the Cardio-thoraco-vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.); and Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, FL (D.C., D.J.A)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.86.5.516"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.595140"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm358"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi505"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eun369"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.016"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024964"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.03.037"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/AC.68.4.2988888"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.018"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0b013e32834df552"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.134486"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.10.61"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.113.000883"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-12-199912210-00004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-9-201111010-00004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.12.18"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.115410"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.03.148"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31828478ac"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq277"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823ba622"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.044"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12219"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.05.020"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.029"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.784"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.114967"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.113.000179"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.11.019"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-3083"},{"key":"e_1_3_2_47_2","first-page":"207","article-title":"The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: facts and questions.","volume":"8","author":"Rubboli A","year":"2011","unstructured":"Rubboli A. The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: facts and questions.J Geriatr Cardiol. 2011;8:207\u2013214.","journal-title":"J Geriatr Cardiol"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.101"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-08-0580"},{"key":"e_1_3_2_50_2","first-page":"572","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.","volume":"106","author":"Faxon DP","year":"2011","unstructured":"Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.Thromb Haemost. 2011;106:572\u2013584.","journal-title":"Thromb Haemost"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.08.021"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.04.012"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.036"},{"key":"e_1_3_2_57_2","unstructured":"Efient (Prasugrel). Highlights of prescribin information.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022307s002lbl.pdf. Accessd November 17 2013."},{"key":"e_1_3_2_58_2","unstructured":"Brilinta (Ticagrelor). Highlights of prescribin information.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022433s008lbl.pdf. Accessed November 17 2013."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.034"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.115386"},{"key":"e_1_3_2_62_2","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.","author":"Alexander JH","year":"2013","unstructured":"Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.Eur Heart J. November 18, 2013.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.063"},{"key":"e_1_3_2_70_2","first-page":"672","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.","volume":"8","author":"Smith JG","year":"2012","unstructured":"Smith JG, Wieloch M, Koul S, Braun O\u00d6, Lumsden J, Rydell E, Ohman J, Scherst\u00e9n F, Svensson PJ, van der Pals J. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.Euro Intervention. 2012;8:672\u2013678.","journal-title":"Euro Intervention"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.112.968792"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs121"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25064"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.750000"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.08.023"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60404-2"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2006.00139.x"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.22527"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.097014"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.08.725"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.022"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61223-9"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5170"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003675"},{"key":"e_1_3_2_86_2","unstructured":"Abbott\u2019s XIENCE PRIME\u2122 and XIENCE V\u00ae Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy.http:\/\/www.abbott.us\/news-media\/press-releases\/abbotts-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-minimum-th.htm. Accessed December 8 2013."},{"key":"e_1_3_2_87_2","unstructured":"Medtronic Approved to Update Resolute Integrity Stent\u2019s \u2018CE\u2019 Mark Labeling on Dual Antiplatelet Therapy.http:\/\/wwwp.medtronic.com\/Newsroom\/NewsReleaseDetails.do?itemId=1361899837211&lang=en_US.Accessed December 8 2013."},{"key":"e_1_3_2_88_2","unstructured":"Palmerini T. Difficult decisions with dual antiplatelet therapy: DES STEMI unplanned treatment interruption.Paper presented at: EuroPCR 14\u201317 May 2012; Paris France."},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","unstructured":"Kirtane A Silber S Neumann F Serruys PW Mauri L Meredith I Windecker S Belardi J Widimsky P Yeung A Saito S Leon M. The relationship between short and long-term antiplatelet therapy use and stent thrombosis following percutaneous coronary intervention with Resolute zotarolimus-eluting stent.Paper Presented at: American College of Cardiology Scientific Sessions 9\u201311 March 2013; San Francisco CA.","DOI":"10.1016\/S0735-1097(13)61862-8"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2011.08.010"},{"key":"e_1_3_2_91_2","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.","volume":"310","author":"Feres F","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela EL, Perin MA, Devito FS, Labrunie A, Salvadori D, Gusm\u00e3o M, Staico R, Costa JR, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.JAMA. 2013;310:2510\u20132522.","journal-title":"JAMA"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.06.015"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278787"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.008"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-1206"},{"key":"e_1_3_2_96_2","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.","volume":"292","author":"Ferguson JJ","year":"2004","unstructured":"Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.JAMA. 2004;292:45\u201354.","journal-title":"JAMA"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.05.022"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.6.696"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.112.972869"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60764-2"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.051"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.2174\/15748901112079990013"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111095"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.3171\/2013.3.JNS12503"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318202f701"},{"key":"e_1_3_2_108_2","unstructured":"Plavix Prescribing Information.http:\/\/products.sanofi.us\/plavix\/plavix.html. Accessed December 6 2013."},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.60"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007964"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.219"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.12.024"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq209"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12058"},{"key":"e_1_3_2_115_2","unstructured":"Prasugrel\u2019s highlights of prescribing information.http:\/\/pi.lilly.com\/us\/effient.pdf. Accessed December 8 2013."},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-4-200508160-00005"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14287-0"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr113"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr334"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_3_2_122_2","unstructured":"Boehringer Ingelheim Planning to Initiate Two New Global Clinical Trials of Pradaxa\u00ae (dabigatran etexilate mesylate).http:\/\/us.boehringer-ingelheim.com\/news_events\/press_releases\/press_release_archive\/2013\/11-19-2013-boehringer-ingelheim-global-clinical-trials-pradaxa-dabigatran-etexilate-mesylate.html. Accessed November 20 2013."}],"container-title":["Circulation: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCINTERVENTIONS.113.001150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:17:24Z","timestamp":1715566644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.113.001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1161\/CIRCINTERVENTIONS.113.001150"],"URL":"https:\/\/doi.org\/10.1161\/circinterventions.113.001150","relation":{},"ISSN":["1941-7640","1941-7632"],"issn-type":[{"value":"1941-7640","type":"print"},{"value":"1941-7632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"2013-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}